|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.27 USD | +4.21% |
|
+2.65% | +6.95% |
| 03/07 | Trial for Ebola treatment starts in DR Congo | RE |
| 02/07 | Trial for Bundibugyo Ebola treatment starts in DRC, WHO says | RE |
| Market Cap | 16TCr 14TCr 13TCr 12TCr 23TCr 15,51800Cr 24TCr 1,57200Cr 61TCr 7,62800Cr 61TCr 60TCr 26,28500Cr | P/E 2026 * |
-46.9x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 17TCr 15TCr 14TCr 13TCr 25TCr 16,42900Cr 25TCr 1,66400Cr 65TCr 8,07600Cr 65TCr 63TCr 27,82900Cr | EV / Sales 2026 * |
5.66x | EV / Sales 2027 * | 5.03x |
| Free-Float |
99.88% | Yield 2026 * |
2.47% | Yield 2027 * | 2.53% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +4.21% | ||
| 1 week | +2.65% | ||
| Current month | +3.90% | ||
| 1 month | +1.62% | ||
| 3 months | -6.04% | ||
| 6 months | +7.95% | ||
| Current year | +6.95% |
| 1 week | 124.19 |  | 131.58 |
| 1 month | 121.39 | | 131.58 |
| Current year | 116.88 | | 157.29 |
| 1 year | 107.75 | | 157.29 |
| 3 years | 62.07 | | 157.29 |
| 5 years | 57.16 | | 157.29 |
| 10 years | 56.56 | | 157.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/07 | Sell | Chief Executive Officer | -15,000 | 0.0012% | ||
| 15/06 | Sell | Chief Financial Officer | -3,000 | 0.0002% | ||
| 15/06 | Sell | Executive/Senior Manager | -3,000 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.21% | +2.65% | +17.47% | +71.11% | 16TCr | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,08200Cr | |
| +3.57% | +3.29% | +68.60% | +61.03% | 63TCr | |
| +3.99% | +3.05% | +37.93% | +93.37% | 46TCr | |
| +3.86% | +1.64% | +31.35% | +24.29% | 34TCr | |
| -0.56% | +0.96% | +39.86% | +36.64% | 30TCr | |
| -0.08% | +1.30% | +30.37% | +44.02% | 29TCr | |
| -1.54% | +2.81% | -27.56% | -39.45% | 22TCr | |
| +3.55% | +4.41% | +25.45% | +66.28% | 20TCr | |
| +1.84% | +0.12% | -4.18% | -33.64% | 14TCr | |
| Average | +2.07% | +4.40% | +27.48% | +48.67% | 38.31TCr | |
| Weighted average by Cap. | +2.23% | +5.43% | +40.12% | +78.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.05TCr 2.66TCr 2.45TCr 2.28TCr 4.33TCr 2,90100Cr 4.39TCr 29TCr 11TCr 1,42600Cr 11TCr 11TCr 4,91300Cr | 3.24TCr 2.83TCr 2.6TCr 2.42TCr 4.6TCr 3,08100Cr 4.67TCr 31TCr 12TCr 1,51400Cr 12TCr 12TCr 5,21900Cr |
| Net income | -337.28Cr -294.85Cr -270.97Cr -252.57Cr -479.06Cr -32TCr -486.32Cr -3.25TCr -1.26TCr -16TCr -1.27TCr -1.24TCr -54TCr | 954.83Cr 834.71Cr 767.1Cr 715.03Cr 1.36TCr 91TCr 1.38TCr 9.21TCr 3.58TCr 45TCr 3.58TCr 3.51TCr 1,54000Cr |
| Net Debt | 956.82Cr 836.45Cr 768.7Cr 716.52Cr 1.36TCr 91TCr 1.38TCr 9.23TCr 3.59TCr 45TCr 3.59TCr 3.51TCr 1,54300Cr | -9.64Cr -8.43Cr -7.75Cr -7.22Cr -14Cr -918.16Cr -14Cr -93Cr -36Cr -451.33Cr -36Cr -35Cr -1.56TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $131.27 | +4.21% | 80,88,800 |
| 01/26/01 | $125.97 | -0.29% | 66,54,936 |
| 30/26/30 | $126.34 | +0.01% | 74,09,570 |
| 29/26/29 | $126.33 | -1.21% | 68,97,708 |
| 26/26/26 | $127.88 | +3.26% | 1,99,08,542 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions
